<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Results</title>
    <link rel="stylesheet" href="./lib/css/styles.css">
</head>
<body class="results">
<p><strong>Asymptomatic patient. Low risk for coronary artery disease. Initial imaging.</strong></p>
Advice from ACR  - https://acsearch.acr.org/docs/3082570/Narrative/
<p><strong>&nbsp;</strong></p>
<p><strong>CT Coronary Calcium or CTA Coronary Arteries with IV Contrast may be appropriate.</strong></p>
<p><strong>No other imaging is usually appropriate.</strong></p>
<p><strong>&nbsp;</strong></p>
<p><strong>CT Coronary Calcium</strong></p>
<p>Studies to date indicate the high prevalence of calcific plaque burden in a high-risk patient, and further testing may be&nbsp; warranted&nbsp; to&nbsp; exclude&nbsp; epicardial&nbsp; stenosis.&nbsp; Data&nbsp; from&nbsp; a&nbsp; large&nbsp; study&nbsp; with&nbsp; 29,312&nbsp; high-risk patients&nbsp; support&nbsp; the&nbsp; rationale&nbsp; of&nbsp; the&nbsp; &ldquo;power&nbsp; of&nbsp; zero&rdquo;;&nbsp; in&nbsp; absence&nbsp; of&nbsp; coronary&nbsp; calcification,&nbsp; only&nbsp; 0.56%&nbsp; participants&nbsp; developed&nbsp; a&nbsp; cardiovascular event during a mean follow-up period of 51 months [40]. A similar observation was also noted in the JUPITER population study in the MESA cohort in which event rates were 0.8 per 1,000 person years with zero calcium score versus 20.2 per 1,000 person years and a calcium score &gt;100. The estimated number needed to treat for 5 years was at 549 in the zero calcium score group versus 42 in the nonzero calcium score group [41].</p>
<p><strong>CTA Coronary Arteries</strong></p>
<p>There&nbsp; is&nbsp; an&nbsp; added&nbsp; value&nbsp; of&nbsp; coronary&nbsp; atherosclerotic&nbsp; plaque&nbsp; burden&nbsp; as&nbsp; a&nbsp; prognostic benefit in&nbsp; addition&nbsp; to&nbsp; the&nbsp; assessment for epicardial stenosis, such that in high-risk asymptomatic patients, CCTA examinations can be useful. Cho et al [42], in their study of 3,217 asymptomatic patients from the CONFIRM registry stratified according to the magnitude of their CAC score, found that CCTA did provide incremental value in patients with a CAC score&gt;100. The incremental value of CCTA over FRS was demonstrated in individuals with CAC scores &gt;100 (likelihood ratio &chi;2, 25.34; increment in C-statistic, 0.24; net reclassification index, 0.62; all P &lt; .001) but not with CAC scores&le;100 (all P &gt; .05). For subgroups with CAC score &gt;100, the utility of CCTA for predicting the study end point was evident among individuals whose CAC score ranged from 101 to 400; the observed predictive benefit attenuated with&nbsp; increasing&nbsp; CAC&nbsp; score. In a&nbsp; high-risk&nbsp; population&nbsp; of&nbsp; 665&nbsp; asymptomatic&nbsp; patients,&nbsp; the&nbsp; multivariate&nbsp; analysis,&nbsp; adjusted for age, gender, and CAC score, obstructive CAD on CCTA (&ge;50% luminal stenosis) was a significant predictor of adverse events (HR, 5.9; CI, 1.3&ndash;26.1). Dedic et al [43] also showed that the addition of CCTA to age and gender, plus a CAC score, increased the C-statistic from 0.81 to 0.84 and resulted in a total net reclassification index of 0.19 (P &lt; .01). Incremental value of the CCTA was also demonstrated by Plank et al [44] in a series of 711 patients,&nbsp; where&nbsp; prevalence&nbsp; of&nbsp; a&nbsp; zero&nbsp; calcium&nbsp; score&nbsp; was&nbsp; 306&nbsp; (43%);&nbsp; out&nbsp; of&nbsp; those,&nbsp; 100&nbsp; (32.7%)&nbsp; had&nbsp; noncalcified&nbsp;</p>
<p>plaque only seen on CTA. With a mean follow-up period of 2.65 years, MACE rate was 0% in CAD negative and higher (1.2%) in CAD positive by CTA. In a large multicenter registry of 27,125 patients (which included both symptomatic and asymptomatic patients), Min et al [45] found that CCTA improved discrimination by maximal stenosis, number of obstructive vessels, and segment stenosis score (C-index 0.77, 0.77, and 0.78, respectively) beyond age, gender, and CAC score (C-index 0.64) in a small subset of 400 asymptomatic patients. Similarly, CCTA findings improved risk reclassification by per&nbsp; patient&nbsp; maximal&nbsp; stenosis&nbsp; (integrated&nbsp; discrimination&nbsp; improvement&nbsp; [IDI]&nbsp; index,&nbsp; 0.03; P&nbsp; =&nbsp; .03)&nbsp; and&nbsp; number&nbsp; of&nbsp; obstructive vessels (IDI index, 0.06; P = .002), and by trend for segment stenosis score (IDI, 0.03; P = .06). In the FACTOR-64 study of 900 asymptomatic patients with both type 1 and 2 diabetes, with a mean follow-up time&nbsp; of&nbsp; 4.0&nbsp; years,&nbsp; the&nbsp; primary&nbsp; outcome&nbsp; event&nbsp; rates&nbsp; were&nbsp; not&nbsp; significantly&nbsp; different&nbsp; between&nbsp; the&nbsp; CCTA&nbsp; and&nbsp; the&nbsp; control groups (6.2% [28 events] versus 7.6% [34 events]; HR, 0.80 [95% CI, 0.49&ndash;1.32]; P = .38) [46]. A study of 517 asymptomatic subjects also showed that CAD- and plaque-positive remodeling increased MACE prediction compared with a model based on 10-year FRS, carotid disease, and CAC score estimation. In the diabetes subgroup, the percentage of segments with remodeled plaque was the only predictor of MACE [47]. In the asymptomatic diabetic population in patients between the ages of 55 and 74, Halon et al [48] demonstrated 2,242 plaques in 499 subjects with 24 patients with acute coronary syndromes during median follow-up of 9.2 years. Additional imaging parameters, like plaque volume (upper versus lower quartile HR, 6.9; 95% CI, 1.6&ndash;30.8; P =.011), percentage of low-density plaque content &lt;50 Hounsfield units (HR, 14.2; 95% CI, 1.9&ndash;108; P = .010), and mild plaque calcification (HR versus all other plaques, 3.3; 95% CI, 1.5&ndash;7.3; P = .004), predicted plaque events univariately after adjustment by clinical risk score. In this series, a culprit plaque event occurred in 13 of 376 (3.5%) high-risk plaques (plaques with &ge;2 risk predictors) versus 11 of 1,866 (0.6%) in non&ndash;high-risk plaques (P &lt; .0001), at 12 of 343 (3.5%) stenotic sites (&ge;50%) versus 12 of 1,899 (0.6%) nonstenotic sites (P &lt; .0001), and in 7 of 131 (5.3%) high-risk&nbsp; plaques&nbsp; with&nbsp; stenosis&nbsp; (P&nbsp; &lt;.0001 versus all&nbsp; others)&nbsp; [48].&nbsp; A&nbsp; systemic&nbsp; review&nbsp; and&nbsp; meta-analysis composed&nbsp; of&nbsp; 10&nbsp; studies,&nbsp; including&nbsp; 5,012&nbsp; asymptomatic&nbsp; participants&nbsp; with&nbsp; diabetes&nbsp; who&nbsp; underwent&nbsp; CCTA,&nbsp; found that presence of obstructive CAD on CCTA (versus nonobstructive or no CAD) was associated with a significantly elevated risk of adverse events (summary HR, 4.07; 95% CI, 2.30&ndash;7.21). Beller et al [49] observed estimated HR for nonobstructive plaque (versus no CAD) was 2.17 (95% CI, 1.11&ndash;4.25). The pooled HRs per unit for segment stenosis&nbsp; score&nbsp; and&nbsp; segment&nbsp; involvement&nbsp; score&nbsp; were&nbsp; 1.44&nbsp; (95%&nbsp; CI,&nbsp; 0.98&ndash;2.12)&nbsp; and&nbsp; 1.73&nbsp; (95%&nbsp; CI,&nbsp; 1.07&ndash;2.80) respectively. The&nbsp; authors&nbsp; concluded&nbsp; that&nbsp; the&nbsp; presence&nbsp; and&nbsp; extent&nbsp; of&nbsp; CAD&nbsp; on&nbsp; CCTA were&nbsp; strong,&nbsp; independent&nbsp; predictors of cardiovascular events in asymptomatic individuals with diabetes</p>
<p><strong>US Echocardiography Transthoracic Resting</strong></p>
<p>There is no relevant literature supporting the use of resting TTE in asymptomatic patients at high risk of CAD.</p>
<p><strong>US Echocardiography Transthoracic Stress</strong></p>
<p>TTE performed at rest and stress can assess for inducible wall-motion abnormalities, thus revealing ischemic heart disease. The&nbsp; sensitivity&nbsp; and&nbsp; specificity&nbsp; of&nbsp; the&nbsp; test&nbsp; is&nbsp; 72%&nbsp; to&nbsp; 83%&nbsp; and&nbsp; 84%&nbsp; to&nbsp; 95%,&nbsp; respectively,&nbsp; and&nbsp; has&nbsp; been&nbsp; validated only in symptomatic elevated risk populations and is best utilized to identify obstructive major epicardial coronary stenosis [20]. There is no relevant literature to support the use of stress TTE in asymptomatic patients at high risk of CAD.</p>
<p><strong>MRA Coronary Arteries</strong></p>
<p>MRA of the coronary arteries can assess for arterial patency and pathologic wall thickening but not calcific burden, and it cannot reliably assess small, distal vessels [35,36]. There is no relevant literature to support the use of MRA of the coronary arteries in asymptomatic patients at high risk of CAD.</p>
<p>&nbsp;</p>
<p><strong>MRI Heart Function with Stress</strong></p>
<p>&nbsp;</p>
<p>There is no relevant literature supporting the use of MRI heart function with stress in asymptomatic patients at high risk of CAD.</p>
<p><strong>MRI Heart Function and Morphology</strong></p>
<p>There is no relevant literature to support the use of MRI heart function and morphology to evaluate asymptomatic patients at intermediate risk of CAD.</p>
<p><strong>SPECT/CT MPI Rest and Stress</strong></p>
<p>Stress SPECT MPI is the most commonly used stress-imaging technique for patients with suspected or known CAD but&nbsp; has&nbsp; been&nbsp; primarily&nbsp; validated&nbsp; in&nbsp; symptomatic&nbsp; patients.&nbsp; Stress&nbsp; SPECT&nbsp; pooled sensitivity&nbsp; and&nbsp; specificity&nbsp; for&nbsp; detection of obstructive CAD (&ge;50% diameter stenosis) was 74%&nbsp; and&nbsp; 79%,&nbsp; respectively,&nbsp; as&nbsp; validated&nbsp; chiefly&nbsp; in&nbsp; symptomatic patients&nbsp; [50].&nbsp; Young&nbsp; et&nbsp; al&nbsp; [51],&nbsp; in&nbsp; their&nbsp; study&nbsp; Detection&nbsp; of&nbsp; Ischemia&nbsp; in&nbsp; Asymptomatic&nbsp; Diabetics&nbsp; (DIAD),&nbsp; a&nbsp; randomized&nbsp; controlled&nbsp; trial,&nbsp; enrolled&nbsp; and&nbsp; randomized&nbsp; 1,123&nbsp; asymptomatic&nbsp; participants&nbsp; with&nbsp; type&nbsp; 2&nbsp; diabetes&nbsp; to&nbsp; either&nbsp; an&nbsp; adenosine-stress&nbsp; radionuclide&nbsp; MPI&nbsp; or&nbsp; no&nbsp; screening&nbsp; imaging,&nbsp; showed&nbsp; the&nbsp; positive&nbsp; predictive&nbsp; value of having moderate or large MPI defects was only 12% with 7 nonfatal myocardial ischemia&rsquo;s and 8 cardiac deaths (2.7%) in the screened MPI group and 10 nonfatal myocardial ischemia&rsquo;s and 7 cardiac deaths (3.0%) among the not-screened group (HR, 0.88; 95% CI, 0.44&ndash;1.88; P = .73). Overall, cardiac event rates were not significantly reduced&nbsp; by&nbsp; MPI&nbsp; screening&nbsp; for&nbsp; myocardial&nbsp; ischemia&nbsp; over&nbsp; 4.8&nbsp; years.&nbsp; In&nbsp; a&nbsp; prospective&nbsp; multicenter&nbsp; BARDOT&nbsp; trial,&nbsp; 22% of asymptomatic&nbsp; high-risk&nbsp; patients&nbsp; with&nbsp; diabetes&nbsp; had&nbsp; abnormal&nbsp; SPECT,&nbsp; but&nbsp; those&nbsp; with&nbsp; abnormal&nbsp; SPECT&nbsp; randomized to medical versus invasive-medical strategies had similar event rates (P = .215) [52]. For a selected subgroup of asymptomatic patients with diabetes, data suggest routine use of SPECT as a screening test is likely to have a lower yield as well as limited effect on clinical outcomes [53]. However, the most recent ACC/AHA/ASNC Appropriate Use Criteria for SPECT MPI states SPECT would be useful when the calcium score is &gt;400 or 100 to 400 if the patient is at high risk of CAD [38].</p><p><strong>References</strong></p>
<ol>
    <li>Cooper R,&nbsp; Cutler&nbsp; J,&nbsp; Desvigne-Nickens&nbsp; P,&nbsp; et&nbsp; al.&nbsp; Trends&nbsp; and&nbsp; disparities&nbsp; in&nbsp; coronary&nbsp; heart&nbsp; disease,&nbsp; stroke,&nbsp; and&nbsp; other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. Circulation2000;102:3137-47.</li>
    <li>Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol2010;56:e50-103.</li>
    <li>Grundy SM,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stone&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NJ,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bailey&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; AL,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; et&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; al.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Guideline&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Management&nbsp; of&nbsp; Blood&nbsp; Cholesterol:&nbsp; A&nbsp; Report&nbsp; of&nbsp; the&nbsp; American&nbsp; College&nbsp; of&nbsp; Cardiology/American&nbsp; Heart&nbsp; Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol2019;73:e285-e350.</li>
    <li>Greenland P, Knoll MD, Stamler J, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA2003;290:891-7.</li>
    <li>Goff DC, Jr., Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a&nbsp; report&nbsp; of&nbsp; the&nbsp; American &nbsp;College&nbsp; of&nbsp; Cardiology/American&nbsp; Heart&nbsp; Association&nbsp; Task&nbsp; Force&nbsp; on&nbsp; Practice&nbsp; Guidelines. J Am Coll Cardiol2014;63:2935-59.</li>
    <li>Wilson SR,&nbsp; Lin&nbsp; FY,&nbsp; Min&nbsp; JK.&nbsp; Role&nbsp; of&nbsp; coronary&nbsp; artery&nbsp; calcium&nbsp; score&nbsp; and&nbsp; coronary&nbsp; CT&nbsp; angiography&nbsp; in&nbsp; the&nbsp; diagnosis&nbsp; and&nbsp; risk&nbsp; stratification&nbsp; of&nbsp; individuals&nbsp; with&nbsp; suspected&nbsp; coronary&nbsp; artery&nbsp; disease.&nbsp; Curr&nbsp; Cardiol&nbsp; Rep2011;13:271-9.</li>
    <li>Perez de Isla L, Alonso R, Muniz-Grijalvo O, et al. Coronary computed tomographic angiography findings and their therapeutic implications in asymptomatic patients with familial hypercholesterolemia. Lessons from the SAFEHEART study. J Clin Lipidol2018;12:948-57.</li>
    <li>Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med2008;358:1336-45.</li>
    <li>American College&nbsp; of&nbsp; Radiology.&nbsp; ACR&nbsp; Appropriateness&nbsp; Criteria&reg;:&nbsp; Acute&nbsp; Nonspecific&nbsp; Chest&nbsp; Pain&mdash;Low Probability of Coronary Artery Disease. Available at: https://acsearch.acr.org/docs/69401/Narrative/. Accessed September 30, 2020.</li>
    <li>Shah AB, Kirsch J, Bolen MA, et al. ACR Appropriateness Criteria&reg; Chronic Chest Pain-Noncardiac Etiology Unlikely-Low to Intermediate Probability of Coronary Artery Disease. J Am Coll Radiol2018;15:S283-S90.</li>
    <li>Akers SR, Panchal V, Ho VB, et al. ACR Appropriateness Criteria&reg; Chronic Chest Pain-High Probability of Coronary Artery Disease. J Am Coll Radiol2017;14:S71-S80.</li>
    <li>Nesto RW, Kowalchuk GJ. The ischemic cascade: temporal sequence of hemodynamic, electrocardiographic and symptomatic expressions of ischemia. Am J Cardiol1987;59:23C-30C.</li>
    <li>American College&nbsp; of&nbsp; Radiology.&nbsp; ACR&ndash;NASCI&ndash;SIR&ndash;SPR&nbsp; Practice&nbsp; Parameter&nbsp; for&nbsp; the&nbsp; Performance&nbsp; and&nbsp; Interpretation&nbsp; of&nbsp; Body&nbsp; Computed&nbsp; Tomography&nbsp; Angiography&nbsp; (CTA).&nbsp; Available&nbsp; at:&nbsp; https://www.acr.org/-/media/ACR/Files/Practice-Parameters/body-cta.pdf. Accessed September 30, 2020.</li>
    <li>Joshi PH, Patel B, Blaha MJ, et al. Coronary artery Calcium predicts Cardiovascular events in participants with a low&nbsp;&nbsp; lifetime&nbsp;&nbsp; risk&nbsp;&nbsp; of&nbsp;&nbsp; Cardiovascular&nbsp;&nbsp; disease:&nbsp;&nbsp; The&nbsp;&nbsp; Multi-Ethnic&nbsp;&nbsp; Study&nbsp;&nbsp; of&nbsp;&nbsp; Atherosclerosis&nbsp;&nbsp; (MESA).&nbsp;&nbsp; Atherosclerosis2016;246:367-73.</li>
    <li>Hecht H, Blaha MJ, Berman DS, et al. Clinical indications for coronary artery calcium scoring in asymptomatic patients: Expert consensus statement from the Society of Cardiovascular Computed Tomography. J Cardiovasc Comput Tomogr2017;11:157-68.</li>
    <li>Dudum R,&nbsp; Dzaye&nbsp; O,&nbsp; Mirbolouk&nbsp; M,&nbsp; et&nbsp; al.&nbsp; Coronary&nbsp; artery&nbsp; calcium&nbsp; scoring&nbsp; in&nbsp; low&nbsp; risk&nbsp; patients&nbsp; with&nbsp; family&nbsp; history of coronary heart disease: Validation of the SCCT guideline approach in the coronary artery calcium consortium. J Cardiovasc Comput Tomogr2019;13:21-25.</li>
    <li>Mitchell JD,&nbsp; Paisley&nbsp; R,&nbsp; Moon&nbsp; P,&nbsp; Novak&nbsp; E,&nbsp; Villines&nbsp; TC.&nbsp; Coronary&nbsp; Artery&nbsp; Calcium&nbsp; and&nbsp; Long-Term&nbsp; Risk&nbsp; of&nbsp; Death,&nbsp; Myocardial&nbsp; Infarction,&nbsp; and&nbsp; Stroke:&nbsp; The&nbsp; Walter&nbsp; Reed&nbsp; Cohort&nbsp; Study.&nbsp; JACC&nbsp; Cardiovasc&nbsp; Imaging2018;11:1799-806.</li>
    <li>Carr JJ, Jacobs DR, Jr., Terry JG, et al. Association of Coronary Artery Calcium in Adults Aged 32 to 46 Years With Incident Coronary Heart Disease and Death. JAMA Cardiol2017;2:391-99.</li>
    <li>Choi EK,&nbsp; Choi&nbsp; SI,&nbsp; Rivera&nbsp; JJ,&nbsp; et&nbsp; al.&nbsp; Coronary&nbsp; computed&nbsp; tomography&nbsp; angiography&nbsp; as&nbsp; a&nbsp; screening&nbsp; tool&nbsp; for&nbsp; the&nbsp; detection of occult coronary artery disease in asymptomatic individuals. J Am Coll Cardiol2008;52:357-65.</li>
    <li>Heijenbrok-Kal MH,&nbsp; Fleischmann&nbsp; KE,&nbsp; Hunink&nbsp; MG.&nbsp; Stress&nbsp; echocardiography,&nbsp; stress&nbsp; single-photon-emission computed tomography and electron beam computed tomography for the assessment of coronary artery disease: a meta-analysis of diagnostic performance. Am Heart J2007;154:415-23.</li>
    <li>Song KD, Kim SM, Choe YH, et al. Integrated cardiac magnetic resonance imaging with coronary magnetic resonance angiography,&nbsp; stress-perfusion,&nbsp; and&nbsp; delayed-enhancement&nbsp; imaging&nbsp; for&nbsp; the&nbsp; detection&nbsp; of&nbsp; occult&nbsp; coronary artery disease in asymptomatic individuals. Int J Cardiovasc Imaging2015;31 Suppl 1:77-89.</li>
    <li>Weir-McCall JR, Fitzgerald K, Papagiorcopulo CJ, et al. Prevalence of unrecognized myocardial infarction in a low-intermediate risk asymptomatic cohort and its relation to systemic atherosclerosis. Eur Heart J Cardiovasc Imaging2017;18:657-62.</li>
    <li>Mordi IR,&nbsp; Badar&nbsp; AA,&nbsp; Irving&nbsp; RJ,&nbsp; Weir-McCall&nbsp; JR,&nbsp; Houston&nbsp; JG,&nbsp; Lang&nbsp; CC.&nbsp; Efficacy&nbsp; of&nbsp; noninvasive&nbsp; cardiac&nbsp; imaging&nbsp; tests&nbsp; in&nbsp; diagnosis&nbsp; and&nbsp; management&nbsp; of&nbsp; stable&nbsp; coronary&nbsp; artery&nbsp; disease.&nbsp; Vasc&nbsp; Health&nbsp; Risk&nbsp; Manag2017;13:427-37.</li>
    <li>Kondos GT,&nbsp; Hoff&nbsp; JA,&nbsp; Sevrukov&nbsp; A,&nbsp; et&nbsp; al.&nbsp; Electron-beam&nbsp; tomography&nbsp; coronary&nbsp; artery&nbsp; calcium&nbsp; and&nbsp; cardiac&nbsp; events:&nbsp; a&nbsp; 37-month&nbsp; follow-up&nbsp; of&nbsp; 5635&nbsp; initially&nbsp; asymptomatic&nbsp; low-&nbsp;&nbsp; to&nbsp; intermediate-risk&nbsp; adults.&nbsp; Circulation2003;107:2571-6.</li>
    <li>Shaw LJ,&nbsp; Raggi&nbsp; P,&nbsp; Schisterman&nbsp; E,&nbsp; Berman&nbsp; DS,&nbsp; Callister&nbsp; TQ.&nbsp; Prognostic&nbsp; value&nbsp; of&nbsp; cardiac&nbsp; risk&nbsp; factors&nbsp; and&nbsp; coronary artery calcium screening for all-cause mortality. Radiology2003;228:826-33.</li>
    <li>Budoff MJ, Shaw LJ, Liu ST, et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol2007;49:1860-70.</li>
    <li>Okwuosa TM, Greenland P, Ning H, Liu K, Lloyd-Jones DM. Yield of screening for coronary artery calcium in early middle-age adults based on the 10-year Framingham Risk Score: the CARDIA study. JACC Cardiovasc Imaging2012;5:923-30.</li>
    <li>Gibson AO, Blaha MJ, Arnan MK, et al. Coronary artery calcium and incident cerebrovascular events in an asymptomatic cohort. The MESA Study. JACC Cardiovasc Imaging2014;7:1108-15.</li>
    <li>Polonsky TS, McClelland RL, Jorgensen NW, et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA2010;303:1610-6.</li>
    <li>Erbel R,&nbsp; Mohlenkamp&nbsp; S,&nbsp; Moebus&nbsp; S,&nbsp; et&nbsp; al.&nbsp; Coronary&nbsp; risk&nbsp; stratification,&nbsp; discrimination,&nbsp; and&nbsp; reclassification&nbsp; improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. J Am Coll Cardiol2010;56:1397-406.</li>
    <li>Mulders TA, Taraboanta C, Franken LC, et al. Coronary artery calcification score as tool for risk assessment among families with premature coronary artery disease. Atherosclerosis2016;245:155-60.</li>
    <li>Nasir K, Rubin J, Blaha MJ, et al. Interplay of coronary artery calcification and traditional risk factors for the prediction of all-cause mortality in asymptomatic individuals. Circ Cardiovasc Imaging2012;5:467-73.</li>
    <li>Di Cesare E, Patriarca L, Panebianco L, et al. Coronary computed tomography angiography in the evaluation of intermediate risk asymptomatic individuals. Radiol Med2018;123:686-94.</li>
    <li>Picano E, Molinaro S, Pasanisi E. The diagnostic accuracy of pharmacological stress echocardiography for the assessment of coronary artery disease: a meta-analysis. Cardiovasc Ultrasound2008;6:30.</li>
    <li>Cruz G,&nbsp; Atkinson&nbsp; D,&nbsp; Henningsson&nbsp; M,&nbsp; Botnar&nbsp; RM,&nbsp; Prieto&nbsp; C.&nbsp; Highly&nbsp; efficient&nbsp; nonrigid&nbsp; motion-corrected&nbsp; 3D&nbsp; whole-heart coronary vessel wall imaging. Magn Reson Med2017;77:1894-908.</li>
    <li>Moghari MH,&nbsp; Roujol&nbsp; S,&nbsp; Henningsson&nbsp; M,&nbsp; et&nbsp; al.&nbsp; Three-dimensional&nbsp; heart&nbsp; locator&nbsp; for&nbsp; whole-heart&nbsp; coronary&nbsp; magnetic resonance angiography. Magn Reson Med2014;71:2118-26.</li>
    <li>Schwitter J,&nbsp; Wacker&nbsp; CM,&nbsp; Wilke&nbsp; N,&nbsp; et&nbsp; al.&nbsp; MR-IMPACT&nbsp; II:&nbsp; Magnetic&nbsp; Resonance&nbsp; Imaging&nbsp; for&nbsp; Myocardial&nbsp; Perfusion Assessment in Coronary artery disease Trial: perfusion-cardiac magnetic resonance vs. single-photon emission&nbsp; computed&nbsp; tomography&nbsp; for&nbsp; the&nbsp; detection&nbsp; of&nbsp; coronary&nbsp; artery&nbsp; disease:&nbsp; a&nbsp; comparative&nbsp; multicentre,&nbsp; multivendor trial. Eur Heart J2013;34:775-81.</li>
    <li>Hendel RC,&nbsp; Abbott&nbsp; BG,&nbsp; Bateman&nbsp; TM,&nbsp; et&nbsp; al.&nbsp; The&nbsp; role&nbsp; of &nbsp;radionuclide&nbsp; myocardial&nbsp; perfusion&nbsp; imaging&nbsp; for&nbsp; asymptomatic individuals. J Nucl Cardiol2011;18:3-15.</li>
    <li>Multimodality Writing&nbsp;&nbsp; Group&nbsp;&nbsp; for&nbsp;&nbsp; Stable&nbsp;&nbsp; Ischemic&nbsp;&nbsp; Heart&nbsp;&nbsp; Disease,&nbsp;&nbsp; Wolk&nbsp;&nbsp; MJ,&nbsp;&nbsp; Bailey&nbsp;&nbsp; SR,&nbsp;&nbsp; et&nbsp;&nbsp; al.&nbsp;&nbsp; ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS&nbsp; 2013&nbsp; multimodality&nbsp; appropriate&nbsp; use&nbsp; criteria&nbsp; for&nbsp; the&nbsp; detection&nbsp; and&nbsp; risk&nbsp; assessment&nbsp; of&nbsp; stable&nbsp; ischemic&nbsp; heart&nbsp; disease:&nbsp; a&nbsp; report&nbsp; of&nbsp; the&nbsp; American&nbsp; College&nbsp; of&nbsp; Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of&nbsp; Echocardiography,&nbsp; American&nbsp; Society&nbsp; of&nbsp; Nuclear&nbsp; Cardiology,&nbsp; Heart&nbsp; Failure&nbsp; Society&nbsp; of&nbsp; America,&nbsp; Heart&nbsp; Rhythm&nbsp; Society,&nbsp; Society&nbsp; for&nbsp; Cardiovascular&nbsp; Angiography&nbsp; and&nbsp; Interventions,&nbsp; Society&nbsp; of&nbsp; Cardiovascular&nbsp; Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. J Card Fail2014;20:65-90.</li>
    <li>Sarwar A,&nbsp; Shaw&nbsp; LJ,&nbsp; Shapiro&nbsp; MD,&nbsp; et&nbsp; al.&nbsp; Diagnostic&nbsp; and&nbsp; prognostic&nbsp; value&nbsp; of&nbsp; absence&nbsp; of&nbsp; coronary&nbsp; artery&nbsp; calcification. JACC Cardiovasc Imaging2009;2:675-88.</li>
    <li>Blaha MJ, Budoff MJ, DeFilippis AP, et al. Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study. Lancet2011;378:684-92.</li>
    <li>Cho I, Chang HJ, B OH, et al. Incremental prognostic utility of coronary CT angiography for asymptomatic patients based upon extent and severity of coronary artery calcium: results from the COronary CT Angiography EvaluatioN For Clinical Outcomes InteRnational Multicenter (CONFIRM) study. Eur Heart J2015;36:501-8.</li>
    <li>Dedic A,&nbsp; Ten&nbsp; Kate&nbsp; GJ,&nbsp; Roos&nbsp; CJ,&nbsp; et&nbsp; al.&nbsp; Prognostic&nbsp; Value&nbsp; of&nbsp; Coronary&nbsp; Computed&nbsp; Tomography&nbsp; Imaging&nbsp; in&nbsp; Patients at High Risk Without Symptoms of Coronary Artery Disease. Am J Cardiol2016;117:768-74.</li>
    <li>Plank F,&nbsp; Friedrich&nbsp; G,&nbsp; Dichtl&nbsp; W,&nbsp; et&nbsp; al.&nbsp; The&nbsp; diagnostic&nbsp; and&nbsp; prognostic&nbsp; value&nbsp; of&nbsp; coronary&nbsp; CT&nbsp; angiography&nbsp; in&nbsp; asymptomatic high-risk patients: a cohort study. Open Heart2014;1:e000096.</li>
    <li>Min JK,&nbsp; Labounty&nbsp; TM,&nbsp; Gomez&nbsp; MJ,&nbsp; et&nbsp; al.&nbsp; Incremental&nbsp; prognostic&nbsp; value&nbsp; of&nbsp; coronary&nbsp; computed&nbsp; tomographic&nbsp; angiography&nbsp; over&nbsp; coronary&nbsp; artery&nbsp; calcium&nbsp; score&nbsp; for&nbsp; risk&nbsp; prediction&nbsp; of&nbsp; major&nbsp; adverse&nbsp; cardiac&nbsp; events&nbsp; in&nbsp; asymptomatic diabetic individuals. Atherosclerosis2014;232:298-304.</li>
    <li>Muhlestein JB, Lappe DL, Lima JA, et al. Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial. JAMA2014;312:2234-43.</li>
    <li>Guaricci AI,&nbsp; Lorenzoni&nbsp; V,&nbsp; Guglielmo&nbsp; M,&nbsp; et&nbsp; al.&nbsp; Prognostic&nbsp; relevance&nbsp; of&nbsp; subclinical&nbsp; coronary&nbsp; and&nbsp; carotid&nbsp; atherosclerosis in a diabetic and nondiabetic asymptomatic population. Clin Cardiol2018;41:769-77.</li>
    <li>Halon DA, Lavi I, Barnett-Griness O, et al. Plaque Morphology as Predictor of Late Plaque Events in Patients With Asymptomatic&nbsp; Type&nbsp; 2&nbsp; Diabetes:&nbsp; A&nbsp; Long-Term &nbsp;Observational&nbsp; Study.&nbsp; JACC&nbsp; Cardiovasc&nbsp; Imaging2019;12:1353-63.</li>
    <li>Beller E,&nbsp; Meinel&nbsp; FG,&nbsp; Schoeppe&nbsp; F,&nbsp; et&nbsp; al.&nbsp; Predictive&nbsp; value&nbsp; of&nbsp; coronary&nbsp; computed&nbsp; tomography&nbsp; angiography&nbsp; in&nbsp; asymptomatic individuals with diabetes mellitus: Systematic review and meta-analysis. J Cardiovasc Comput Tomogr2018;12:320-28.</li>
    <li>Takx RA, Blomberg BA, El Aidi H, et al. Diagnostic accuracy of stress myocardial perfusion imaging compared to invasive&nbsp; coronary&nbsp; angiography&nbsp; with&nbsp; fractional&nbsp; flow&nbsp; reserve&nbsp; meta-analysis.&nbsp; Circ&nbsp; Cardiovasc&nbsp; Imaging2015;8:1-7.</li>
    <li>Young LH, Wackers FJ, Chyun DA, et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA2009;301:1547-55.</li>
    <li>Zellweger MJ, Maraun M, Osterhues HH, et al. Progression to overt or silent CAD in asymptomatic patients with diabetes mellitus at high coronary risk: main findings of the prospective multicenter BARDOT trial with a pilot randomized treatment substudy. JACC Cardiovasc Imaging2014;7:1001-10.</li>
    <li>Budoff MJ,&nbsp; Raggi&nbsp; P,&nbsp; Beller&nbsp; GA,&nbsp; et&nbsp; al.&nbsp; Noninvasive&nbsp; Cardiovascular&nbsp; Risk&nbsp; Assessment&nbsp; of&nbsp; the&nbsp; Asymptomatic&nbsp; Diabetic&nbsp; Patient:&nbsp; The&nbsp; Imaging&nbsp; Council&nbsp; of&nbsp; the&nbsp; American&nbsp; College&nbsp; of&nbsp; Cardiology.&nbsp; JACC&nbsp; Cardiovasc&nbsp; Imaging2016;9:176-92.</li>
    <li>American College&nbsp; of&nbsp; Radiology.&nbsp; ACR&nbsp; Appropriateness&nbsp; Criteria&reg;&nbsp; Radiation&nbsp; Dose&nbsp; Assessment&nbsp; Introduction.&nbsp; Available&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; at:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; https://www.acr.org/-/media/ACR/Files/Appropriateness-Criteria/RadiationDoseAssessmentIntro.pdf. Accessed September 30, 2020.</li>
</ol></body>
</html>